MRI Methods for Evaluating the Effects of Tyrosine Kinase Inhibitor Administration Used to Enhance Chemotherapy Efficiency in a Breast Tumor Xenograft Model

Journal of Magnetic Resonance Imaging

Volumn 29, Issue 5, 2009, Pages 1071-1079

  Aliu, S O ^a,b,d   Wilmes, L J ^a   Moasser, M M ^a   Hann, B C ^c   Li, K L ^a   Wang, D ^c   Hylton, N M ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Chemotherapy; Diffusion weighted imaging; Dynamic Contrast enhanced; Gefitinib; Tyrosine kinase inhibitor; Xenograft tumor model

Indexed keywords

GEFITINIB; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; QUINAZOLINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST TUMOR; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL DENSITY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; DRUG EFFECT; DRUG PULSE THERAPY; EVALUATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; MAXIMUM TOLERATED DOSE; MEASUREMENT; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PLASMA VOLUME; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TUMOR VOLUME; XENOGRAFT; ANIMAL; DISEASE MODEL; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG ANTAGONISM; METHODOLOGY; NUDE MOUSE; OUTCOME ASSESSMENT; PROGNOSIS; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MICE; MICE, NUDE; OUTCOME ASSESSMENT (HEALTH CARE); PROGNOSIS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; QUINAZOLINES;

EID: 66149129193     PISSN: 10531807     EISSN: 15222586     Source Type: Journal    
DOI: 10.1002/jmri.21737     Document Type: Article

References (41)

1. Yarden Y. The EGFR family and its ligands in human cancer. Signaling mechanisms and therapeutic opportunities. Eur J Cancer 2001;37 (Suppl 4) :3-8.
2. Rose-Hellekant TA, Sandgren EP. Transforming growth factor alpha- and c-myc-induced mammary carcinogenesis in transgenic mice. Nature 2000;19:1092-1096.
3. Ellis LM. Epidermal growth factor receptor in tumor angiogenesis. Hematol Oncol Clin North Am 2004;18:1007-1021.
4. Kumar R, Yarmand-Bagheri R. The role of HER2 in angiogenesis. Semin Oncol 2001;28 (5 Suppl 16) :27-32.
5. Moasser MM, Basso A, Averbuch SD, Rosen N. The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res 2001;61:7184-7188.
6. Moulder S, Yakes F, Muthuswamy S, Bianco R, Simpson J, Arteaga C. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2) -overexpressing breast cancer cells in vitro and in vivo. Cancer Res 2001;61:8887-8895.
7. Ciardiello F, Caputo R, Bianco R, et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 2000;6:2053-2063.
8. Sirotnak FM, Zakowski MF, Miller VA, Scher HI, Kris MG. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 2000;6:4885-4892.
9. Sergina NV, Rausch M, Wang D, et al. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 2007;445:437-441.
10. Turetschek K, Preda A, Floyd E, et al. MRI monitoring of tumor response following angiogenesis inhibition in an experimental human breast cancer model. Eur J Nucl Med Mol Imaging 2003;30: 448-455.
11. Neil JJ. Measurement of water motion (apparent diffusion) in biological systems. Concepts Magn Reson 1997;9:385-401.
12. Gupta RK, Cloughesy TF, Sinha U, et al. Relationships between choline magnetic resonance spectroscopy, apparent diffusion coefficient and quantitative histopathology in human glioma. J Neurooncol 2000;50:215-226.
13. Gupta RK, Sinha U, Cloughesy TF, Alger JR. Inverse correlation between choline magnetic resonance spectroscopy signal intensity and the apparent diffusion coefficient in human glioma. Magn Reson Med 1999;41:2-7.
14. Pickles MD, Gibbs P, Lowry M, Turnbull LW. Diffusion changes precede size reduction in neoadjuvant treatment of breast cancer. Magn Reson Med 2006;24:843-847.
15. Yankeelov TE, Lepage M, Chakravarthy A, et al. Integration of quantitative DCE-MRI and ADC mapping to monitor treatment response in human breast cancer: initial results. Magn Reson Imaging 2007;25:1-13.
16. Galons J-P, Altbach MI, Paine-Murrieta GD, Taylor CW, Gillies RJ. Early increases in breast tumor xenograft water mobility in response to paclitaxel therapy detected by non-invasive diffusion magnetic resonance imaging. Neoplasia 1999;1:113-117.
17. Rubesova E, Grell A-S, Maertelaer VD, Metens T, Chao S-L, Lemort M. Quantitative diffusion imaging in breast cancer: a clinical prospective study. J Magn Reson Imaging 2006;24:319-324.
18. Guo Y, Cai Y, Cai Z, et al. Differentiation of clinically benign and malignant breast lesions using diffusion-weighted imaging. J Magn Reson Imaging 2002;16:172-178.
19. Kuroki Y, Nasu K, Kuroki S, et al. Diffusion-weighted imaging of breast cancer with the sensitivity encoding technique: analysis of the apparent diffusion coefficient value. Magn Reson Med Sci 2004; 3:79-85.
20. Woodhams R, Matsunaga K, Iwabuchi K, et al. Diffusion-weighted imaging of malignant breast tumors: the usefulness of apparent diffusion coefficient (ADC) value and ADC map for the detection of malignant breast tumors and evaluation of cancer extension. J Comput Assist Tomogr 2005;29:644-649.
21. Padhani AR. MRI for assessing antivascular cancer treatments. Br J Radiol 2003;76:S60-80.
22. Knopp MV, Weiss E, Sinn HP, et al. Pathophysiologic basis of contrast enhancement in breast tumors. J Magn Reson Imaging 1999;10:260-266.
23. Su M-Y, Wang Z, Nalcioglu O. Investigation of longitudinal vascular changes in control and chemotherapy-treated tumors to serve as therapeutic efficacy predictors. J Magn Reson Imaging 1999;9: 128-137.
24. Taylor JS, Tofts PS, Port R, et al. MR imaging of tumor microcirculation: Promise for the new millennium. J Magn Reson Imaging 1999;10:903-907.
25. Turetschek K, Preda A, Novikov V, et al. Tumor microvascular changes in antiangiogenic treatment: assessment by magnetic resonance contrast media of different molecular weights. J Magn Reson Imaging 2004;20:138-144.
26. Partridge SC, McKinnon GC, Henry RG, Hylton NM. Menstrual cycle variation of apparent diffusion coefficients measured in the normal breast using MRI. J Magn Reson Imaging 2001;14:433-438.
27. Bezdek JC. Pattern recognition with fuzzy objective function algorithm. New York: Plenum; 1981.
28. Klifa C, Carballido-Gamio J, Wilmes L, et al. Quantification of breast tissue index from MR data using fuzzy clustering. San Francisco: IEEE; 2004.
29. Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab 1983;3:1-7.
30. Tofts PS, Kermode AG. Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. Magn Reson Med 1991;17:357-367.
31. Daldrup H, Shames DM, Wendland M, et al. Correlation of dynamic contrast-enhanced magnetic resonance imaging with histologic tumor grade: comparison of macromolecular and small-molecular contrast media. Pediatr Radiol 1998;28:67-78.
32. Moasser M, Wilmes L, Wong C, et al. Improved tumor vascular function following high dose epidermal growth factor receptor tyrosine kinase inhibitor therapy. J Magn Reson Imaging 2007;26: 1618-1625.
33. Solit DB, She Y, Lobo J, et al. Pulsatile administration of the epidermal growth factor receptor inhibitor gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel. Clin Cancer Res 2005;11:1983-1989.
34. Lyng H, Haraldseth O, Rofstad EK. Measurement of cell density and necrotic fraction in human melanoma xenografts by diffusion weighted magnetic resonance imaging. Magn Reson Med 2000;43: 828-836.
35. Checkley D, Tessier JJ, Kendrew J, Waterton JC, Wedge SR. Use of dynamic contrast-enhanced MRI to evaluate acute treatment with ZD6474, a VEGF signalling inhibitor, in PC-3 prostate tumours. Br J Cancer 2003;89:1889-1895.
36. Li K-L, Wilmes LJ, Henry RG, et al. Heterogeneity in the angiogenic response of a BT474 human breast cancer to a novel vascular endothelial growth factor-receptor tyrosine kinase inhibitor: assessment by voxel analysis of dynamic contrast-enhanced MRI. J Magn Reson Imaging 2005;22:511-519.
37. Marzola P, Degrassi A, Calderan L, et al. Early antiangiogenic activity of SU11248 evaluated in vivo by dynamic contrast-enhanced magnetic resonance imaging in an experimental model of colon carcinoma. Clin Cancer Res 2005;11:5827-5832.
38. Pham CD, Roberts TL, Bruggen Nv, et al. Magnetic resonance imaging detects suppression of tumor vascular permeability after administration of antibody to vascular endothelial growth factor. Cancer Invest 1998;16:225-230.
39. Viloria-Petit A, Crombet T, Jothy S, et al. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res 2001;61:5090-5101
40. Pradel C, Siauve N, Bruneteau G, et al. Reduced capillary perfusion and permeability in human tumour xenografts treated with the VEGF signalling inhibitor ZD4190: an in vivo assessment using dynamic MR imaging and macromolecular contrast media. Magn Reson Imaging 2003;21:845-851.
41. Drevs J, Müller-Driver R, Wittig C, et al. PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging. Cancer Res 2002;62:4015-4022.